Abstract-Preclinical studies in animal models and early results of clinical trials in patients suggest that intramuscular injection of naked plasmid DNA
R ecent investigations have established the feasibility of using recombinant formulations or gene transfer of angiogenic growth factors to expedite and augment collateral artery development in patients with tissue ischemia. [1] [2] [3] [4] Such postnatal neovascularization was initially considered synonymous with proliferation and migration of preexisting, fully differentiated endothelial cells (ECs) resident within parent vessels, ie, angiogenesis. 5, 6 The demonstration, however, of postnatal circulating bone marrow-derived endothelial progenitor cells (EPCs) that may home to sites of neovascularization and differentiate into ECs in situ 7 is consistent with "vasculogenesis," 6 a critical paradigm for establishment of the primordial vascular network in the embryo. Although the proportional contributions of angiogenesis and vasculogenesis to neovascularization of adult organisms remain to be clarified, the notion that growth and development of new blood vessels in the adult is not restricted to angiogenesis but encompasses both embryonic mechanisms has now been verified by several laboratories. 8 -10 Among the mechanisms that may modulate the contribution of vasculogenesis to postnatal neovascularization, we considered that certain angiogenic growth factors, which are acknowledged to promote both angiogenesis and vasculogenesis in the embryo 11 but have been assumed to promote neovascularization exclusively by angiogenesis in the adult, [12] [13] [14] may in fact promote migration, proliferation, and mobilization of EPCs from adult bone marrow. Indeed, investigations performed in our laboratory using a bone marrow transplant model established that vascular endothelial growth factor (VEGF) may mobilize EPCs from murine bone marrow, resulting in augmented neovascularization. 15 Accordingly, the current study was designed to test the hypothesis that intramuscular gene transfer of naked plasmid DNA encoding human VEGF (phVEGF 165 ) may increase the number of circulating human EPCs in patients with critical limb ischemia.
Materials and Methods

Study Subjects
The potential for VEGF to enhance the population of circulating EPCs was serially monitored in 20 patients (11 women and 9 men, age 59Ϯ16 years) undergoing intramuscular phVEGF 165 gene trans-fer for critical limb ischemia. The same studies were performed on 9 patients who did not receive phVEGF 165 gene therapy. Four of these were healthy volunteers (4 men) ranging in age from 30 to 43 years (36Ϯ3), who were injected with normal saline. The remaining 5 patients included 2 women and 3 men with critical limb ischemia ages 48 to 78 years (67Ϯ12), who had been randomly assigned to receive a control (empty) vector.
Intramuscular phVEGF 165 Transfer
The patients undergoing gene therapy received the eukaryotic expression vector pUC118 encoding VEGF 165 transcriptionally regulated by the cytomegalovirus promoter/enhancer. A total of 4000 g of DNA in 8 aliquots of 2.5 mL of sterile saline was administered at different sites into the ischemic limb by direct intramuscular injection.
Plasma VEGF Levels
Plasma levels of VEGF were measured by an ELISA assay in patients before intramuscular injection and weekly up to 4 weeks after the initial set of injections. 3 
Isolation of Mononuclear Cells (MNCs)
Blood samples were obtained from all individuals before and, weekly, up to 4 weeks after intramuscular injections. Peripheral blood MNCs were isolated in a cell preparation tube by density gradient centrifugation.
EPC Culture Assay
The culture system used in our laboratory to quantify circulating EPCs has been described elsewhere. 15 MNCs from 500 L of peripheral blood were cultured in EC basal medium-2 supplemented with endothelial cell growth medium (EGM-2) microvascular (MV) Single Quots. After 4 days, fluorescence staining of adherent cells was used to detect the binding of Ulex europaeus agglutinin I (UEA-1) and the uptake of acetylated LDL (acLDL). Dual-staining cells positive for both FITC-labeled UEA-1 and 1,1Ј-dioctadecyl-3,3,3Ј,3Ј-tetramethylindocarbocyanine (DiI)-labeled acLDL were judged as EPCs and counted per well.
Flow Cytometry Analysis
A total of 2 to 3ϫ10 5 cells were incubated for 30 minutes at 4°C with monoclonal antibodies prepared against KDR, VE-cadherin, CD62E (E-selectin), CD51/61 (␣ v ␤ 3 ), CD31, CD34, and CD14. Quantitative fluorescence-activated cell sorter (FACS) analysis was performed on a FACStar flow cytometer.
Statistical Analysis
All results are expressed as meanϮSEM. Statistical significance was evaluated using unpaired Student t test and ANOVA. A value of PϽ0.05 was interpreted to denote statistical significance. The relationship between variables was determined by linear regression analysis.
An expanded Materials and Methods section is available online at http://www.circresaha.org.
Results
To evaluate the effect of VEGF on EPC kinetics, we obtained 100 samples of peripheral blood from patients with critical limb ischemia undergoing VEGF 165 gene transfer. A total of 25 samples were obtained from patients in whom injection of empty DNA vector was performed. An additional 20 samples were obtained from healthy individuals who received saline injections.
Transgene Expression After VEGF Gene Therapy
Plasma levels of VEGF transiently increased in all patients after gene transfer. A mean 2.1Ϯ0.3-fold increase over baseline at day 7 (PϽ0.001) was followed by persistent elevation at day 14 (1.9Ϯ0.3-fold, PϽ0.001), day 21 (1.8Ϯ0.2-fold, PϽ0.01), and day 28 (1.5Ϯ0.2-fold, PϽ0.05, all versus baseline). The mean plasma VEGF concentrations increased from 33.1Ϯ5 pg/mL at baseline to a maximum value of 98.8Ϯ17 pg/mL after gene transfer (PϽ0.01). In contrast, no significant changes were documented in the control patients ( Figure 1 ).
EPC Culture Assay After phVEGF 165 Gene Therapy
Two independent criteria were used to assess the effect of phVEGF 165 gene transfer on EPC kinetics. First, we applied a previously described 15 culture assay in which EPCs were quantified by identification of cultured cells demonstrating both UEA-1 reactivity and uptake of acLDL ( Figure 2 ). The impact of VEGF on circulating EPCs could be detected by culture assay from day 7 (80% increase versus baseline, PϽ0.0005) through day 14 (154% increase versus baseline, PϽ0.0005), day 21 (82% increase versus baseline, PϽ0.05), and day 28 after treatment (153% increase versus baseline, PϽ0.005). The increase in EPCs correlated with the rise in VEGF plasma levels (R 2 ϭ0.83; PϽ0.0001) ( Figure 1B online; available at http://www.circresaha.org). Patients injected with empty vector had comparable numbers of EPCs at baseline but failed to exhibit a significant change in cultured EPCs. The number of cultured EPCs was significantly different between the VEGF-treated patients and the control vector-injected group as early as day 7 (PϽ0.001) and over the following 3 weeks (day 14, PϽ0.005; day 21, PϽ0.05; Figure 1 . VEGF plasma levels and circulating EPCs of patients before and after intramuscular administration of phVEGF 165 or empty vector. Concomitant with a significant rise in the VEGF plasma levels as determined by ELISA, the number of EPCs determined by the culture assay in the phVEGF 165 -treated group increased as early as treatment day 7 through posttreatment day 28. In contrast, no change in VEGF plasma levels or EPCs was observed in the control group. *PϽ0.01, **PϽ0.001, and ***PϽ0.0005 for increase of EPCs over baseline; #PϽ0.05, ##PϽ0.01, and ###PϽ0.001 for increase of VEGF plasma over baseline.
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day 28, PϽ0.005). Likewise, the saline-injected group showed no significant change in EPC counts over 4 weeks after gene transfer. There was no significant difference in EPC count between the saline-and empty vector-treated groups ( Figure 1 ).
FACS Analysis
FACS analysis was used as a second independent measure to quantify the population of EPCs mobilized in response to VEGF gene transfer. Overall, we observed an average increase in the expression levels of the EC-specific antigens KDR (22.1Ϯ1. (Figure 3 ). In contrast, no significant changes were observed in the group injected with empty plasmid or in the group of healthy volunteers injected with saline. Likewise, the number of CD14-positive cells remained unchanged in all 3 study groups (data not shown). Representative of the measurements taken at the aforementioned time points, Figure 4 shows the expression values at day 14. The increase over baseline in VEGF plasma levels and in VE-cadherin-positive cells showed a high correlation at this time point (R 2 ϭ0.82; PϽ0.0001) ( Figure 1C online; available at http://www.circresaha.org). Findings in the VEGF-treated group differed significantly from both control groups.
To determine the relationship between the culture assay and the FACS analysis, we compared the individual increases in both assays at a representative time point (day 14), using the rise in the EPC count and in the number of VE-cadherin positive cells. The results revealed a positive correlation (R 2 ϭ0.77; PϽ0.0005) ( Figure 1A online; available at http://www.circresaha.org).
Expression of EC Adhesion Molecules
We also examined the effect of VEGF gene transfer on the expression of EC adhesion molecules. In patients subjected to VEGF gene transfer, the number of circulating MNCs with the surface expression of ␣ v ␤ 3 (CD51/61) and E-selectin (CD62E) increased during the observation period on average by 5Ϯ1-fold and 25Ϯ1-fold, respectively. In contrast, expression values in individuals receiving empty vector and saline treatment remained unchanged. The expression pattern and levels of E-selectin were very similar to those of VE-cadherin and KDR, with maximal values at day 7 and day 28 after the treatment, whereas the levels for ␣ v ␤ 3 were slightly different with a maximal expression at day 14. At the representative time point, day 14, levels of ␣ v ␤ 3 and E-selectin expression in the VEGF-treated group increased significantly compared with baseline (for ␣ (Figure 4 ).
Discussion
Preclinical studies in animal models 16 and early studies performed in small numbers of patients with lower limb 17 and myocardial 2, 4 ischemia support the notion that gene transfer of VEGF DNA may promote neovascularization of ischemic tissues. These previous reports established that direct injection of phVEGF 165 into muscle of the ischemic limb, 3, 17 as well as into ischemic myocardium, 2 transiently elevates plasma VEGF levels in the systemic circulation, a finding that is confirmed in the patients described above.
The current series of patients further establishes that the rise in plasma levels of VEGF is associated with modulation of EPC kinetics after VEGF gene transfer. The increase in EPCs was statistically significant as early as 1 week after gene transfer and remained statistically significant at 2, 3, and 4 weeks follow-up. By comparison, EPC kinetics in the control subjects-including patients with or without critical limb ischemia, injected with empty vector or saline-were unchanged.
Because of limitations in the types of analyses that may be performed in human subjects, the origin and fate of the augmented population of circulating EPCs in these patients must be inferred from experiments performed previously in live animal models. Daily intraperitoneal injection of recombinant human VEGF 165 (rhVEGF) to C57BL/6J mice for 1 week increased the total number of circulating EPCs. 15 These effects were abrogated by coincidental application of a neutralizing antibody prepared against rhVEGF.
When mice were pretreated with rhVEGF or control buffer for 7 days before cornea micropocket injury and then examined on day 7 after injury (ie, 7 days after the last dose of rhVEGF), in situ BS-1 lectin staining disclosed enhanced corneal neovascularization in the rhVEGF group compared with controls. These findings were reproduced in mice receiving bone marrow transplanted from transgenic mice constitutively expressing ␤-galactosidase encoded by lacZ under the transcriptional regulation of an EC-specific gene, tie-2, to establish direct evidence for incorporation of bone marrow-derived EPCs into capillaries and stromal tissue of the corneal neovasculature.
Like fully differentiated ECs, 18 EPCs express specific endothelial antigens, including KDR (VEGF receptor-2), CD34, and VE-cadherin. 8, 9, 19 Although KDR and VEcadherin are generally considered to distinguish EPCs from hematopoietic stem cells, 20, 21 there exists no epitope of which the expression is restricted exclusively to EPCs versus fully differentiated ECs. There is, however, evidence that EPCs constitute the preponderance of such circulating, bone marrow-derived endothelial lineage cells. First, the present work indicates that the population of circulating EPCs in normal individuals (3 to 5ϫ10 3 /mL) far exceeds the number of differentiated ECs circulating in peripheral blood (2 to 3/mL). 22 Second, animal experiments from our own laboratory have suggested that the majority of the cellular population mobilized into the circulation and then incorporated into neovascular foci after VEGF administration is most consistent with bone marrow-derived EPCs. 15 These clinical findings call into question certain fundamental concepts regarding the mechanisms by which VEGF promotes blood vessel growth and development in adult organisms. The role of VEGF in postnatal neovascularization has been previously considered synonymous with proliferation and migration of preexisting, fully differentiated ECs resident within parent vessels, ie, sprout formation or angiogenesis. 6, 12, 18 The finding that VEGF augments the number of circulating EPCs in human patients, together with the aforementioned murine experiments, 15 implies that its impact on postnatal neovascularization is the combined result of vasculogenesis as well as angiogenesis. The proportional contributions of angiogenesis and vasculogenesis to postnatal neovascularization, including the extent to which each is influenced by VEGF, remain to be clarified.
Finally, these findings have implications for the use of naked DNA in human gene therapy. Earlier studies suggested that the low transfection efficiency associated with the use of naked DNA might make it unsuitable for therapeutic appli- cations in trials of human gene therapy. Subsequent experience in live animal models, however, demonstrated that transfer of genes encoding for secreted proteins, such as VEGF, could yield important biological effects due to the paracrine effects of the secreted gene product. 23 The current demonstration that VEGF gene therapy augments the compartment of circulating EPCs constitutes further evidence that gene transfer of naked DNA may indeed be sufficient to modulate the biology of human subjects.
